Method for use of IGF-binding protein for selective sensitization of target cells in vivo

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,371,813
App. No.: 10/778,636
Granted: May 13, 2008
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

Claims (7)

1. An insulin-like growth factor binding protein-derived peptide said peptide consist of a sequence selected from the group consisting of

DKKGFYKKKQCRPSKGRKRGFCW

(SEQ ID NO: 1)

and

QCRPSKGRKRGFCW

(SEQ ID NO: 2).

2. The peptide of claim 1 , wherein said peptide consists of the sequence QCRPSKGRKRGFCW (SEQ ID NO: 2).

Assignments (5)

PATENT SECURITY AGREEMENT Recorded Oct 20, 2022

From: INSMED INCORPORATED

To: BIOPHARMA CREDIT PLC